A 52-week Study of Rilzabrutinib Efficacy and Safety Compared to Placebo in Adults Diagnosed With IgG4-related Disease
← catalyst calendarNCT07190196 · readout in 679 d
Sponsored by Sanofi (industry) · SNY — their whole pipeline →.
Phase
Phase 3
Status
Recruiting
Study type
Interventional
Design
Randomized · Quadruple · Treatment
Enrollment
124estimated
Sites
79
Countries
Argentina, Belgium, Canada +16
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2025-09-26 | actual | When the study began enrolling |
| Primary completion | 2028-06-28 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2030-12-25 | estimated | The whole study's end, after follow-up |
| First posted | 2025-09-24 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-07-28 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Immunoglobulin G4 Related Disease
Interventions
- Drug: Rilzabrutinib — also filed as SAR444671
- Drug: Placebo
- Drug: Glucocorticoid
Primary outcome
what the primary-completion date above is the date OFTime to first adjudicated clinical disease flare treated by the investigator during the Blinded Treatment period
measured Until Week 52
Permalink · SNY's whole pipeline · Catalyst calendar · Every registered study · What changed